Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 13,555 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total value of $246,972.10. Following the completion of the transaction, the chief financial officer owned 145,355 shares in the company, valued at $2,648,368.10. This represents a 8.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $54,074.75.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $34,158.30.

Bicara Therapeutics Stock Up 0.8%

NASDAQ:BCAX traded up $0.14 during trading hours on Friday, hitting $18.64. 84,025 shares of the company traded hands, compared to its average volume of 484,864. The company has a market cap of $1.02 billion, a PE ratio of -8.32 and a beta of -0.78. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71. The firm’s 50-day simple moving average is $16.43 and its 200-day simple moving average is $15.70.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Neutral Sentiment: Company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) — a routine hire-related award but one that can create modest dilution expectations. Bicara Therapeutics Announces Inducement Grant
• Neutral Sentiment: Short-interest entries posted for early March report “large increases” but show 0 shares/NaN changes — this appears to be a data error and is not informative about genuine shorting pressure.
• Negative Sentiment: CFO Ivan Hyep sold a total of 16,518 shares across March 3–4 at ~ $18.22–$18.25, reducing his stake (~2–8.5% reductions in separate filings). Large, disclosed CFO sales can weigh on sentiment. Ivan Hyep SEC Form 4
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 at an average ~$18.16 (~7.8% reduction). Significant sales by operating leadership can signal personal liquidity-taking and may pressure the stock. Ryan Cohlhepp SEC Form 4
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (200 and 16,300 shares) at ~ $18.45–$18.52, representing a ~22.8% reduction in one filing. Large founder/executive selling is commonly viewed negatively by the market. David Raben SEC Form 4

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. boosted its position in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after purchasing an additional 2,771,868 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at approximately $44,484,000. Vestal Point Capital LP boosted its holdings in Bicara Therapeutics by 80.6% in the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after buying an additional 2,231,025 shares during the period. Franklin Resources Inc. purchased a new position in Bicara Therapeutics in the 4th quarter valued at approximately $27,265,000. Finally, State Street Corp grew its stake in Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wells Fargo & Company boosted their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Citizens Jmp started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target for the company. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.